Diabetic neuropathy is associated with increased morbidity and mortality. To date, limited data in subjects with impaired glucose tolerance and diabetes demonstrate nerve fiber repair after intervention. This may reflect a lack of efficacy of the interventions but may also reflect difficulty of the tests currently deployed to adequately assess nerve fiber repair, particularly in short-term studies. Corneal confocal microscopy (CCM) represents a novel noninvasive means to quantify nerve fiber damage and repair. Fifteen type 1 diabetic patients undergoing simultaneous pancreas–kidney transplantation (SPK) underwent detailed assessment of neurologic deficits, quantitative sensory testing (QST), electrophysiology, skin biopsy, corneal sensitivity, and CCM at baseline and at 6 and 12 months after successful SPK. At baseline, diabetic patients had a significant neuropathy compared with control subjects. After successful SPK there was no significant change in neurologic impairment, neurophysiology, QST, corneal sensitivity, and intraepidermal nerve fiber density (IENFD). However, CCM demonstrated significant improvements in corneal nerve fiber density, branch density, and length at 12 months. Normalization of glycemia after SPK shows no significant improvement in neuropathy assessed by the neurologic deficits, QST, electrophysiology, and IENFD. However, CCM shows a significant improvement in nerve morphology, providing a novel noninvasive means to establish early nerve repair that is missed by currently advocated assessment techniques.

Corneal Confocal Microscopy Detects Early Nerve Regeneration in Diabetic Neuropathy After Simultaneous Pancreas and Kidney Transplantation

Mitra Tavakoli,1 Maria Mitu-Pretorian,2 Ioannis N. Petropoulos,1 Hassan Fadavi,1 Omar Asghar,1 Uazman Alam,1 Georgios Ponirakis,1 Maria Jezierska,3 Andy Marshall,4 Nathan Efron,5 Andrew J. Boulton,1 Titus Augustine,2 and Rayaz A. Malik1

Diabetic neuropathy is one of the most common long-term complications of diabetes and underlies the development of painful neuropathy in 21% of both type 1 and type 2 diabetic patients (1). It is the main initiating factor for foot ulceration and lower extremity amputation (2). At present we have no treatment to repair nerve fibers and improve diabetic neuropathy. Even in the Diabetes Control and Complications Trial (DCCT) and follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study, improved glycemic control only delayed the progression of clinical diabetic neuropathy and indeed nerve conduction studies at closeout showed no significant risk reduction (3). Furthermore, the Steno-2 study demonstrated that although multifactorial intervention showed an improvement in retinopathy, nephropathy, and cardiac autonomic neuropathy, there was no benefit for somatic neuropathy (4). Even in the most dramatic example of “curing” type 1 diabetes with pancreas transplantation, in 115 patients followed over 10 years, neurologic function, nerve conduction studies, and autonomic function were only prevented from worsening and failed to show an improvement (5). This is in keeping with the lack of improvement in heart rate variability, 43 months after simultaneous pancreas–kidney transplantation (SPK) (6) and intraepidermal nerve fiber density (IENFD) 2.5 years after SPK (7). Neuropathy is of course extremely severe at this stage, as evidenced by severe intraepidermal nerve fiber depletion in pancreas transplant recipients, suggesting either a point of no return or the need for long-term follow-up to identify posttransplant nerve fiber regeneration (8). However, IENFD and corneal nerve morphology have been shown to improve in subjects with impaired glucose tolerance neuropathy (9) and in patients with type 2 diabetes (10), respectively, after improvement in metabolic risk factors.

To establish efficacy of a new treatment, ideally an improvement in diabetic neuropathy has to be shown. Although current end points have a good ability to diagnose diabetic neuropathy (11), their ability to define a therapeutic response may have significant limitations (12). This may indeed be a major reason why clinical trials in human diabetic neuropathy have failed to reach prespecified primary end points such as neuropathic deficits and electrophysiology (13). The assessments of neurologic symptoms and deficits have recently been shown to have poor diagnostic reproducibility (14). Although electrophysiology correlates with large fiber damage, it does not assess small fibers, which are the earliest to be damaged (15) and demonstrate repair even in advanced neuropathy (12). Nerve fiber morphology in sural nerve biopsies (16) and IENFD in skin-punch biopsies (17) can accurately quantify nerve fiber damage and repair, but both are invasive procedures.

We and others (18,19) have used corneal confocal microscopy (CCM) to detect subclinical diabetic neuropathy and relate it to the severity of somatic neuropathy (20) and IENFD (21) with good sensitivity and specificity (20). This led us to propose that CCM, a noninvasive and reiterative test, might be an ideal surrogate end point for evaluating
therapeutic efficacy in clinical trials of human diabetic neuropathy (22). In a preliminary study, we have previously shown a significant improvement in corneal nerve fiber density (CNFD) and length 6 months after SPK (23), but at that time we did not compare CCM with established end points of diabetic neuropathy. In the current study we have compared CCM with neurologic deficits, quantitative sensory testing (QST), electrophysiology, and IENFD at baseline and 6 and 12 months after SPK to help define the measures that may best detect an improvement in diabetic neuropathy after intervention.

RESEARCH DESIGN AND METHODS

Selection of patients. Fifteen type 1 diabetic patients were evaluated at baseline and 6 and 12 months after SPK and compared with 10 age-sex-matched nondiabetic healthy control subjects. The healthy volunteers were recruited from the general population. Both patients and control subjects underwent full neurologic and medical assessments. Those patients with any history of systemic (apart from diabetes for patient group) or neurologic conditions or history of ocular trauma and those wearing contact lens or those who had had ocular surgery were excluded. The study was approved by the Central Manchester Ethics Committee, and written informed consent was obtained according to the Declaration of Helsinki.

Assessment of neuropathy. All patients and control subjects underwent a detailed evaluation of neurologic symptoms according to the neuropathy symptom profile (NSP), and the McGill pain analog score was used to assess the severity of painful neuropathy. Neurologic deficits were assessed using the modified neuropathy disability score (NDS), which includes evaluation of vibration, thermal (cool and warm sensation), and pin prick, as well as the presence or absence of ankle reflexes to establish the severity of neuropathy; NDS 0–2, no neuropathy; NDS 3–5, mild neuropathy; NDS 6–8, moderate neuropathy; and NDS 9–10, severe neuropathy. Quantitative sensory testing included an assessment of vibration perception threshold (VPT), measured on the foot, and the changes in heart rate were displayed on an ECG monitor. Two eight-cycle breathing series were completed interspersed by a 5-min period of normal breathing. The acquired data were analyzed by calculating the mean difference between the highest and lowest heart rate for five consecutive, artifact-free cycles in each eight-cycle series.

Electro-diagnostic studies were undertaken using a Dantec “Keypoint” system (Dantec Dynamics, Bristol, U.K.) equipped with a Danish Industri Syndak na temperature regulator to keep the test temperature constant between 32°C and 35°C. Peroneal motor and sural sensory nerves were assessed in the right lower limb by a consultant neurophysiologist. The motor study was performed using silver-silver chloride surface electrodes at standardized sites defined by anatomical landmarks, and recordings for the sural nerve were taken using antidromic stimulation over a distance of 100 mm.

Corneal sensitivity. Corneal sensitivity was quantified using a noncontact cornal aesthesiometer (NCCA) (Glasgow Caledonian University, Glasgow, Scotland, U.K.), which uses a puff of air through a nose 0.5 mm in diameter lasting 0.9 s and exerting a force expressed in millibars (mbars) (25). The stimulus jet is mounted on a slit lamp and is positioned 1 cm from the eye, and the air jet is aligned to the center of the cornea. Each subject was presented with a supramaximal stimulus, and the staircase method was used by reducing the stimulus strength until the patient did not feel the jet on three occasions, to establish the threshold. The coefficient of variation for NCCA was 5.6%.

CCM. Patients underwent examination with the Heidelberg retina tomograph III in vivo corneal confocal microscope. The subject’s eyes were anesthetized using a drop of 0.4% benoxinate hydrochloride, and Viscotears were applied on the front of the eye for lubrication. A drop of viscoelastic gel was placed on the tip of the objective lens, and a sterile disposable Perspex cap was placed over the optical coupling of the objective lens to the cornea. The patient was instructed to fixate on a target with the eye not being examined. Several scans of the entire depth of the cornea were recorded by turning the fine focus of the objective lens backward and forward for ~2 min using the section mode, which enables manual acquisition and storage of single images of all corneal layers. This provides an end-to-face-dimensional images with a lateral resolution of ~2 μm/pixel and final image size of 400 × 400 pixels of the subbasal nerve plexus of the cornea from each patient and control subject. This layer is of particular relevance for defining neuropathic changes since it is the location of the main nerve plexus that supplies the overlying corneal epithelium. Each nerve fiber bundle contains unmyelinated fibers, which run parallel to Bowman’s layer before dividing and terminating as individual axons underneath the surface epithelium (26). Five images per patient from the center of the cornea were selected and examined in a masked and randomized fashion (27). Three corneal nerve parameters were quantified: 1) CNFD, the total number of major nerves per square millimeter of corneal tissue; 2) corneal nerve branch density (CNBD), the number of branches emanating from all major nerve trunks per 1 mm2 of corneal tissue; and 3) corneal nerve length (CNFL), the total length of all nerve fibers and branches (mm/mm2) within the area of corneal tissue. CCFD and CNFL are considered to reflect overall nerve fiber degeneration, whereas CNBD reflects nerve fiber regeneration, which is partially also captured by CNFL.

Skin biopsy and immunohistochemistry. A 3-mm punch skin biopsy was taken from the dorsum of the foot ~2 cm above the second metatarsal head after local anesthesia (1% lidocaine). The biopsy site was closed using Steri-strips, and the specimen was immediately fixed in PBS-buffered 4% paraformaldehyde. After 18–24 h, it was rinsed in Tris-buffered saline and soaked in 33% sucrose (2–4 h) for cryoprotection. It was then embedded in optimal cutting temperature–embedding compound, rapidly frozen in liquid nitrogen, and cut into 50-μm sections using a cryostat (model OMP; Bright Instruments, Huntington, U.K.). Four floating sections per subject were subjected to melanin bleaching (0.25% KMnO4 for 15 min followed by 5% oxalic acid for 3 min), rinsed in 0.1 M sodium borate buffer, and placed in a 4-h protein block with a Tris-buffered saline solution of 5% normal swine serum, 0.5% powdered milk, and 1% Triton X-100, and overnight incubation with 1:200 Biogenes polyclonal rabbit anti-human PGP9.5 antibody (Serotec, Oxford, U.K.). Biotinylated swine anti-rabbit secondary antibody (1:300; DakoCytomation, Ely, U.K.) was then applied for 1 h; sections were washed with PBS (3×5 min) and then incubated with 1:500 horseradish peroxidase–streptavidin (Vector Laboratories, Peterborough, U.K.). Nerve fibers were demonstrated using 3, 3′-diaminobenzidine chromogen (Sigma-Aldrich, Manchester, U.K.). Sections were mildly counterstained with eosin to better localize the basement membrane to identify nerve fibers passing through it. Negative control subjects consisted of replacing the anti-PGP9.5 antibody with rabbit immunoglobulin (DakoCytomation) at 1:200 in the primary antibody step, which showed no immunostaining. IENFD, i.e., the number of fibers per millimeter of basement membrane, was quantified in accord with established criteria and techniques and expressed as number per millimeter (28).

Statistics. SPSS 16.0.5 for Windows was used to compute the results. Analysis included descriptive and frequency statistics. All data are expressed as means ± SEM. A paired sample t test was used to test whether a sample mean (of a normally distributed interval variable) differed between control subjects and diabetic patients at baseline and at follow-up 6 and 12 months after SPK.

RESULTS

The clinical characteristics and detailed assessment of neuropathy in diabetic patients and age-matched control subjects are summarized in Table 1. BMI was nonsignificantly lower in diabetic patients and showed an increase after SPK. HbA1C was higher in diabetic patients compared with control subjects and improved into the normal range at 6 and 12 months after SPK, but this was not statistically significant. The total cholesterol was significantly lower (P = 0.01) in diabetic patients and remained the same at 6 and 12 months after SPK. Both HDL and triglycerides were comparable between diabetic patients and control subjects, and remained unchanged after SPK. The estimated glomerular filtration rate was lower in diabetic patients at baseline (P = 0.02) and did not change significantly at 6 and 12 months after SPK.

Symptoms and neurologic deficits. Neuropathic symptoms as assessed with the NSP were significantly greater in diabetic patients than in control subjects at baseline (P = 0.005), but there was no significant improvement at 6 (P = 0.1) or 12 (P = 0.9) months after transplantation. The McGill pain index was significantly (P = 0.01) greater at baseline compared with control subjects and did not show a significant change at 6 (P = 0.9) or 12 (P = 0.9) months after transplantation. The modified NDS was significantly lower after SPK (P = 0.005). The time to walk unaided was also significantly lower in diabetic patients at baseline (P = 0.001) and remained significantly lower after SPK (P < 0.05). Diabetic polyneuropathy was significantly more severe at baseline (P < 0.05) and remained significantly more severe after SPK (P < 0.05) in diabetic patients.
TABLE 1
Clinical demographic results in control subjects and type 1 diabetic patients undergoing SPK at baseline and follow-up visits at 6 and 12 months

| Parameter                        | Control subjects | Baseline | Follow-up |
|----------------------------------|------------------|----------|-----------|
|                                  |                  |          | 6 months  | 12 months |
| **n (female/male)**              | 10 (3/7)         | 15 (5/10)| 15        | 15        |
| **Age (years)**                  | 47 ± 3           | 47 ± 3   | —         | —         |
| **Diabetes duration (years)**    | 0                | 27 ± 3.5 | —         | —         |
| **BMI (kg/m²)**                  | 27 ± 1           | 22 ± 2   | 25.5 ± 1  | 25.5 ± 1  |
| **HbA1c (%)**                    | 5.7 ± 0.1        | 7.4 ± 0.8| 5.9 ± 0.3 | 5.9 ± 0.4 |
| **Cholesterol (mmol/L)**         | 5.1 ± 0.2        | 4.0 ± 0.3| 4.3 ± 0.3 | 4.5 ± 0.3 |
| **HDL (mmol/L)**                 | 1.5 ± 0.1        | 1.3 ± 0.2| 1.5 ± 0.2 | 1.6 ± 0.2 |
| **Triglycerides (mmol/L)**       | 1.3 ± 0.2        | 1.4 ± 0.1| 1.2 ± 0.1 | 1.03 ± 0.1|
| **Estimated glomerular filtration rate (mL/min/L)** | 86.22 ± 2.13 | 60.53 ± 8.64† | 64.0 ± 7.5 | 66.0 ± 6.19 |

Data are presented as mean ± SEM in diabetic patients and control subjects unless otherwise indicated. All symbols represent statistically significant differences using paired sample t test. *P < 0.01. †P < 0.02 (baseline vs. control).

(P = 0.003) greater at baseline compared with control subjects, indicating a mild to moderate neuropathy, and did not change significantly at 6 (P = 0.7) or 12 (P = 0.8) months after transplantation (Table 2).

**Quantitative sensory tests.** VPT was significantly greater in diabetic patients compared with control subjects at baseline (P = 0.01) and did not change significantly at 6 (P = 0.1) or 12 (P = 0.6) months after transplantation. CS was significantly greater in diabetic patients compared with control subjects at baseline (P = 0.004) and did not change significantly at 6 (P = 0.5) or 12 (P = 0.5) months after transplantation. WS was significantly greater in diabetic patients compared with control subjects at baseline (P = 0.005) and did not change significantly at 6 (P = 0.9) or 12 (P = 0.4) months after transplantation.

**Autonomic function.** Average heart rate variability was significantly lower in diabetic patients compared with control subjects at baseline (P = 0.01) and did not change significantly at 6 (P = 0.9) or 12 (P = 0.8) months after transplantation. Sural nerve conduction velocity and amplitude were significantly lower in diabetic patients compared with control subjects at baseline (P = 0.003, P = 0.001, respectively) and did not change significantly at 6 (P = 0.7, P = 0.9) or 12 (P = 0.6, P = 0.3) months after transplantation (Table 2).

**IENFD.** IENFD was significantly lower in diabetic patients compared with control subjects at baseline (P < 0.0001) and did not show a significant improvement 12 months after transplantation (P = 0.9) (Fig. 1 and Table 3).

**Corneal sensation.** The corneal sensation threshold was significantly greater in diabetic patients compared with control subjects at baseline (P = 0.03) and did not change at 6 (P = 0.9) or 12 (P = 0.9) months after transplantation (Table 3).

**CCM.** Representative images from a diabetic patient at baseline show a marked reduction in subbasal corneal nerves with a progressive repair at 6 and 12 months after SPK. CNFD was significantly lower in diabetic patients compared with control subjects at baseline (P < 0.0001), did not improve at 6 months (P = 0.7), but reached statistical significance at 12 months (P = 0.02). Similarly, CNFL was significantly lower in diabetic patients compared with control subjects at baseline (P < 0.0001) and did not improve at 6 months (P = 0.2) but reached statistical significance at

TABLE 2
Clinical neuropathy evaluation in control subjects and type 1 diabetic patients undergoing SPK at baseline and follow-up visits at 6 and 12 months

| Parameter                        | Control subjects | Baseline | Follow-up |
|----------------------------------|------------------|----------|-----------|
|                                  |                  |          | 6 months  | 12 months |
| **NSP (0–38)**                   | 0                | 6.7 ± 1.8| 7.6 ± 2.2 | 7.3 ± 2.0 |
| **NDS (0–10)**                   | 0.3 ± 0.2        | 4.6 ± 0.9| 5.0 ± 1.1 | 5.4 ± 0.7 |
| **McGill pain index**            | 1.7 ± 0.6        | 1.9 ± 0.8| 1.3 ± 0.5 |
| **VPT (volts)**                  | 6.7 ± 1.8        | 19.4 ± 3.7| 17.4 ± 3.3| 16.9 ± 3.4|
| **CS (°C)**                      | 29.3 ± 0.4       | 17.5 ± 3.1| 19.8 ± 2.9| 20.0 ± 2.7|
| **WS (°C)**                      | 38.1 ± 0.8       | 43.7 ± 1.4| 43.8 ± 1.2| 42.3 ± 1.1|
| **Heart rate variability (average bpm)** | 15.3 ± 2.1 | 7.1 ± 1.7 | 5.7 ± 1.7 | 4.9 ± 2.1 |
| **Sural nerve conduction velocity (m/s)** | 47.9 ± 0.5 | 40.6 ± 2.2 | 41.5 ± 1.6 | 41.8 ± 1.9 |
| **Sural amplitude (μA)**         | 20.7 ± 3.4       | 5.1 ± 0.9 | 5.1 ± 0.9 | 4.0 ± 0.6 |
| **Peroneal nerve conduction velocity (m/s)** | 47.7 ± 0.9 | 35.9 ± 1.8 | 37.7 ± 1.2 | 38.5 ± 1.8 |
| **Peroneal amplitude (mV)**      | 12.2 ± 0.9       | 2.4 ± 0.4 | 1.9 ± 0.4 | 1.7 ± 0.3 |

Data are presented as mean ± SEM in diabetic patients and control subjects. All symbols represent statistically significant differences using paired sample t test. *P < 0.05. †P < 0.01. ‡P < 0.001 (baseline vs. control; 6 months vs. baseline; 12 months vs. baseline).
12 months ($P = 0.03$). CNBD was significantly lower in diabetic patients compared with control subjects at baseline ($P < 0.0001$) but showed a significant improvement ($P = 0.03$) at 6 months and continued to improve significantly ($P = 0.008$) at 12 months (Figs. 2 and 3).

Although IENFD did not show an improvement at 12 months, it showed a significant correlation with corneal nerve parameters including CNFD ($P = 0.656$, $r < 0.0001$), CNBD ($P = 0.709$, $r < 0.0001$), and CNFL ($P = 0.695$, $r < 0.0001$).

**DISCUSSION**

The natural history of nerve damage in patients with type 1 diabetes is not entirely clear. Longitudinal data from the Rochester cohort support the contention that the duration and severity of exposure to hyperglycemia are related to the progression and hence severity of neuropathy rather than its onset (29). In type 1 diabetes the development of diabetic neuropathy has been related not only to glycemic control but also to conventional cardiovascular risk factors such as hypertension and lipids (30). The Toronto consensus identified clinical and neurophysiologic evaluation combined with quantitative sensory and autonomic function testing as well as small fiber evaluation to diagnose neuropathy (11). However, there is no clear consensus as to the critical end points, which should be used to define the benefits of therapeutic intervention.

The cure for type 1 diabetes is via pancreas transplantation, which normalizes blood glucose. Over the past 20 years, the survival and mortality of SPK transplants has improved significantly (31); therefore, it provides the ideal intervention to assess whether the long-term complications of diabetes are reversible. Some studies show that retinopathy can deteriorate in 10–35% of patients with unstable eye disease immediately after pancreas transplantation, but benefits do become apparent after several years (32,33). Other studies demonstrate an improvement and/or stabilization of diabetic retinopathy after a median follow-up of only 17 months (34,35). For nephropathy, normoglycemia can stop the progression of diabetic glomerulopathy, but does not reverse it (36,37). Similarly, pancreas transplantation alone can limit further reduction in glomerular filtration rate (33), and SPK protects the graft kidney from developing diabetic nephropathy (38).

With regard to neuropathy, pancreas transplantation has previously been shown to improve nerve conduction and motor and sensory action potentials in the upper but not the lower limb as well as sudomotor function (5), within 1 year, but with no impact on autonomic function (5–7). SPK has been shown to improve gastric emptying and symptoms related to gastroparesis compared with kidney transplantation alone (39), although gastrointestinal symptoms and autonomic deficits do not correlate with each other. In a recent study in 18 type 1 diabetic patients there was no improvement in IENFD 21–40 months post-SPK (7). However, most patients receiving transplantation had severe nerve fiber damage as evidenced by marked depletion of intraepidermal nerve fibers (8). Although nerve conduction studies and quantitative sensory testing are useful and well-validated measures to help diagnose and assess the progression of diabetic neuropathy, their utility in evaluating a therapeutic response may be limited (40). More detailed and reproducible measures, which accurately quantify small fiber neuropathy via skin or nerve biopsy, may be more sensitive but are invasive (15–17). There is now an increasing literature on the potential for CCM to quantify C-fiber pathology in peripheral neuropathies (18,41,42). Detailed morphometric and immunohistological studies have demonstrated that the subbasal nerve fiber bundles studied by CCM are
predominantly nociceptive C fibers (43,44). Indeed, CCM has been applied to evaluate diabetic neuropathy (19,20), idiopathic small fiber neuropathy (45), and Fabry disease (46). We have shown that corneal nerve damage assessed using CCM relates to the severity of intraepidermal nerve fiber loss (21) and is related to a loss of corneal sensitivity (25) in diabetic neuropathy. CCM detects very early small-fiber damage even in subjects with an elevated HbA1c, still within the normal range (18), and HbA1c levels 7–10 years before CCM correlate with the severity of nerve damage (47). Furthermore, an improvement in HbA1c by optimizing medical therapy (10) and pancreas transplantation (23) led to corneal nerve regeneration, shown using CCM. However, in these studies the evaluation of neuropathy was limited to CCM.

The present study allowed us to evaluate the relative ability of CCM to detect nerve fiber repair compared with all other established measures for assessing neuropathy, including neurologic deficits, QST, neurophysiology, and IENFD. The results demonstrate a severe neuropathy in diabetic patients before SPK as evidenced by significant abnormalities in electrophysiology, QST, IENFD, and corneal nerve fibers, confirming previous studies (5–8). However, despite this considerable baseline damage, we now show a significant improvement in corneal nerve branch density within 6 months of transplantation. This improvement confirms our previous work (23) indicating an early nerve-fiber repair process with the restoration of euglycemia, followed by a significant improvement in nerve-fiber density and nerve-fiber length 12 months after SPK. This is in contrast to all other standard measures of neuropathy, including detailed QST, autonomic function, electrophysiology, and IENFD, all of which failed to show an improvement 12 months after SPK. These findings support previous studies in diabetic neuropathy where at best a prevention of progression in nerve damage was shown only after several years of euglycemia (5–8,48–51). However, these studies focused heavily on electrophysiology and quantitative sensory assessment, which predominantly assessed large fiber function. It is relevant that where small fiber function was assessed in the form of sudomotor function, a significant improvement was demonstrated within 1 year of SPK (5,7). The main limitations of this study are the small number of subjects studied, the

| Parameter               | Control subjects | Baseline       | 6 months | 12 months |
|-------------------------|------------------|----------------|----------|-----------|
| NCCA (mbars)            | 0.56 ± 0.1       | 1.78 ± 0.42*   | 1.83 ± 0.73 | 1.84 ± 0.89 |
| CNFD (no./mm²)          | 35.77 ± 1.53     | 14.44 ± 1.20‡  | 15.22 ± 1.63 | 19.27 ± 1.57* |
| CNBD (no./mm²)          | 100.92 ± 13.1    | 21.46 ± 3.78‡  | 36.85 ± 6.04* | 43.02 ± 6.48↑ |
| CNFL (mm/mm²)           | 27.93 ± 1.26     | 11.35 ± 1.04‡  | 13.35 ± 1.50 | 15.63 ± 1.56* |
| IENFD (no./mm)          | 9.77 ± 1.24      | 2.03 ± 0.61‡   | —         | 2.31 ± 1.17  |

Data are presented as mean ± SEM in diabetic patients and control subjects. Note that skin biopsy was not performed at 6 months. All symbols represent statistically significant differences using paired sample t test. *P < 0.05. †P < 0.01. ‡P < 0.001 (baseline vs. control; 6 months vs. baseline; 12 months vs. baseline).

FIG. 2. CCM images from Bowman’s layer of cornea: a control subject (A) and patient with type 1 diabetes at baseline (B) and at 6 (C) and 12 (D) months after SPK. The red arrows indicate main nerve fibers, and yellow arrows indicate branches. (A high-quality color representation of this figure is available in the online issue.)
FIG. 3. CNFD (left), CNBD (middle), and CNFL (right) in diabetic patients at baseline and at 6 and 12 months after SPK. *P < 0.05; †P < 0.01; ‡P < 0.001 (baseline vs. control; 6 months vs. baseline; 12 months vs. baseline).

posibility of false-positive results based on the number of comparisons, the lack of sudomotor testing given its previous improvement in these patients, and the lack of blinding given that all patients were known to have had a SPK during the follow-up period. Furthermore, with regard to the lack of improvement in IENFD, this may reflect the location of the skin biopsy as we assessed this on the dorsum of the foot, whereas a previous study (9) has shown that proximal IENFD assessment in the thigh is more responsive to intervention. Similarly, for neurophysiological assessment it has been suggested that upper limb neurophysiology may show a better response to intervention as a result of lesser severity of damage (52).

We now confirm and extend the results of our previous study using the latest generation Heidelberg retina tomograph III, which provides enhanced small fiber imaging and detects earlier nerve fiber repair, particularly reflected in the increase in nerve branch density, followed by significant improvements in nerve fiber density and length. We believe these data provide further support for the need to study small fibers as surrogate markers and end points in intervention trials of diabetic neuropathy. An important issue with regard to the utility of CCM or indeed any surrogate end point has to be that these alterations in corneal nerve morphology predict deterioration of neuropathy and ultimately clinically meaningful outcomes such as foot ulceration. An alternative interpretation of this data could of course be that CCM is measuring something unique that is not an accurate biomarker of how other peripheral nerves are faring or indeed that corneal nerves respond well to restoration of insulin and normoglycemia, whereas other peripheral nerves do not. Nevertheless, CCM appears to represent a promising noninvasive and hence reiterative test with high sensitivity, which may represent an ideal surrogate end point for assessing the benefits of pancreas transplantation and indeed other therapies in clinical trials of human diabetic neuropathy.

ACKNOWLEDGMENTS

This work was supported by National Institutes of Health Grant R105091.

No potential conflicts of interest relevant to this article were reported.

M.T. researched and analyzed the data and wrote the manuscript. M.M.-P. and T.A. were the transplant surgeons.

L.N.P. researched data and analyzed CCM images. H.F., O.A., and U.A. undertook clinical and neurological assessment, skin biopsy, and QST. G.P. was the study coordinator. M.J. undertook IENFD assessments. A.M. undertook neurophysiology. N.E. reviewed and revised the manuscript. A.J.B. reviewed and revised the manuscript. R.A.M. supervised the project, undertook IENFD assessment, and reviewed and revised the manuscript. R.A.M. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Support from the Wellcome Trust Clinical Research Facility is acknowledged.

REFERENCES

1. Abbott CA, Malik RA, van Rossen ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011;34:2220–2224
2. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005;366:1719–1724
3. Albers JW, Herman WH, Pop-Busui R, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010;33:1090–1096
4. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–589
5. Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 1997;41:727–736
6. Boucek P, Saudek F, Adamc M, et al. Spectral analysis of heart rate variation following simultaneous pancreas and kidney transplantation. Transplant Proc 2003;35:1494–1498
7. Boucek P, Havrdova T, Voska L, et al. Epidermal innervation in type 1 diabetic patients: a 2.5-year prospective study after simultaneous pancreas/kidney transplantation. Diabetes Care 2008;31:1611–1612
8. Boucek P, Havrdova T, Voska L, et al. Severe depletion of intraepidermal nerve fibers in skin biopsies of pancreas transplant recipients. Transplant Proc 2005;37:3574–3575
9. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for prediabetic neuropathy. Diabetes Care 2006;29:1294–1299
10. Tavakoli M, Kalimikos P, Iqbal A, et al. Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med 2011;28:1261–1267
11. Tesfaye S, Boulton AJ, Dyck PJ, et al.; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33:2285–2290
12. Malik R, Veves A, Tesfaye S, et al.; on behalf of the Toronto Consensus Panel on Diabetic Neuropathy*. Small fiber neuropathy: Role in the diagnosis of diabetic sensorimotor polyneuropathy. Diabetes Metab Res Rev 2011;27:678–684
13. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN I trial. Diabetes Care 2011;34:2054–2060
14. Dyck PJ, Overland CJ, Low PA, et al.; CI vs. NPhys Trial Investigators. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: CI vs. NPhys trial. Muscle Nerve 2010;42:157–164
15. Malik RA, Veves A, Walker D, et al. Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology. Acta Neuropathol 2001;101:367–374
16. Malik RA, Tesfaye S, Newrick PG, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia 2005;48:578–585
17. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003;60:108–111
18. Ahmed A, Brl V, Orszag A, et al. Detection of diabetic sensorimotor polyneuropathy by corneal confocal microscopy in type 1 diabetes: a concurrent validity study. Diabetes Care 2012;35:821–828
19. Rosenberg ME, Tervo TM, Inmonen JI, Muller LJ, Gronhagen-Riska C, Vesaluoma MH. Corneal structure and sensitivity in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci 2001;41:2915–2921
20. Tavakoli M, Quattrini C, Abbott C, et al. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care 2010;33:1792–1797
21. Quattrini C, Tavakoli M, Jezierska M, et al. Surrogate markers of small fibre damage in human diabetic neuropathy. Diabetes 2007;56:2148–2154
22. Hossain P, Sachdev A, Malik RA. Early detection of diabetic peripheral neuropathy with corneal confocal microscopy. Lancet 2005;366:1019–1020
23. Mehta S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care 2007;30:2608–2612
24. Bravenboer B, van Dam PS, Hop J, vd Steenhoven J, Erkelens DW. Thermal threshold testing for the assessment of small fibre dysfunction: normal values and reproducibility. Diabet Med 1992;9:546–549
25. Tavakoli M, Kallinikos PA, Efron N, Boulton AJ, Malik RA. Corneal sensitivity is reduced and relates to the severity of neuropathy in patients with diabetes. Diabetes Care 2007;30:1895–1897
26. He J, Bazan HE. Mapping the nerve architecture of diabetic human corneas. Ophthalmology 2012;119:956–964
27. Tavakoli M, Malik RA. Corneal confocal microscopy: a novel non-invasive technique to quantify small fibre pathology in peripheral neuropathies. J Vis Exp 2011;47:2194
28. Lauria G, Bakkers M, Schnitz C, et al. Intraneuronal fibre density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst 2010;15:202–207
29. Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ 3rd, O’Brien PC. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999;22:1470–1486
30. Tesfaye S, Chaturvedi N, Eaton SE, et al.; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352:341–350
31. Demartines N, Schiesser M, Clavien PA. An evidence-based analysis of simultaneous pancreas-kidney and pancreas transplantation alone. Am J Transplant 2005;5:2688–2697
32. Wang Q, Klein R, Moss SE, et al. The influence of combined kidney-pancreas transplantation on the progression of diabetic retinopathy. A case series. Ophthalmology 1994;101:1071–1076
33. White SA, Shaw JA, Sutherland DE. Pancreas transplantation. Lancet 2000;356:1808–1817
34. Giannarelli R, Coppelli A, Sartini M, et al. Effects of pancreas-kidney transplantation on diabetic retinopathy. Transpl Int 2005;18:619–622
35. Giannarelli R, Coppelli A, Sartini MS, et al. Pancreas transplant alone has beneficial effects on retinopathy in type 1 diabetic patients. Diabetologia 2006;49:2977–2982
36. Fioretto P, Mauer SM, Bilous RW, Goetz FC, Sutherland DE, Steffes MW. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet 1995;346:1193–1196
37. Florina P, Perseghin G, De Cobelli F, et al. Altered kidney graft high-energy phosphate metabolism in kidney-transplanted end-stage renal disease type 1 diabetic patients: a cross-sectional analysis of the effect of kidney alone and kidney-pancreas transplantation. Diabetes Care 2007;30:597–603
38. Nyuuru M, Honda K, Babazono T, et al. A long-term prevention of diabetic nephropathy in a patient with type 1 diabetes after simultaneous pancreas and kidney transplantation. Clin Transplant 2009;23(Suppl. 20):54–57
39. Hathaway DK, Hartwig MS, Milstead J, Elmer D, Evans S, Garber AO. Improvement in quality of life reported by diabetic recipients of kidney-only and pancreas-kidney allografts. Transplant Proc 1994;26:512–514
40. Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49:229–239
41. Hertz P, Bril V, Orszag A, et al. Reproducibility of in vivo corneal confocal microscopy as a novel screening test for early diabetic sensorimotor polyneuropathy. Diabet Med 2011;28:1253–1260
42. Pritchard N, Edwards K, Shahidi AM, et al. Corneal markers of diabetic neuropathy. Ocul Surf 2011;9:17–28
43. Muller LJ, Marfurt CF, Kruse F, Tervo TM. Corneal nerves: structure, contents and function. Exp Eye Res 2003;76:521–542
44. Muller LJ, Vrensen GF, Pols L, Cardozo BN, Willekens B. Architecture of human corneal nerves. Invest Ophthalmol Vis Sci 1997:38:985–994
45. Tavakoli M, Marshall A, Pitecaithly R, et al. Corneal confocal microscopy: A novel means to detect nerve fibre damage in idiopathic small fibre neuropathy. Exp Neurol 2010;223:245–250
46. Tavakoli M, Marshall A, Thompson L, et al. Corneal confocal microscopy: a novel noninvasive means to diagnose neuropathy in patients with Fabry disease. Muscle Nerve 2009;40:976–984
47. Fukashi I, Okino M, Ishibashi M, et al. Corneal nerve fiber pathology in Japanese type 1 diabetic patients and its correlation with antecedent glycemic control and blood pressure. J Diabetes Invest 2012;3:191–198
48. Kennedy WR, Navarro X, Goetz FC, Sutherland DE, Najarjan JS. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990;322:1031–1037
49. Kennedy WR, Navarro X, Sutherland DE. Neuropathy profile of diabetic patients in a pancreas transplantation program. Neurology 1995;45:773–780
50. Navarro X, Kennedy WR, Aeppli D, Sutherland DE. Neuropathy and mortality in diabetes: influence of pancreas transplantation. Muscle Nerve 1996;19:1009–1016
51. Navarro X, Kennedy WR, Loewenson RB, Sutherland DE. Influence of pancreas transplantation on cardiorespiratory reflexes, nerve conduction, and mortality in diabetes mellitus. Diabetes 1990;39:802–806
52. Allen RD, Al-Harbi IS, Morris JG, et al. Diabetic neuropathy after pancreas transplantation: determinants of recovery. Transplantation 1997;63:830–838